Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer’s disease

Aleksandra Klimkowicz-Mrowiec1 Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, PolandCorrespondence[email protected]

Pawel Wolkow2 Department of Pharmacology, Jagiellonian University, School of Medicine, Grzegórzecka, Poland

Malgorzata Sado3 Department of Neurology, University Hospital, Botaniczna, Krakow, Poland

ANNA Dziubek3 Department of Neurology, University Hospital, Botaniczna, Krakow, Poland

Joanna Pera1 Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, Poland

Tomasz Dziedzic1 Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, Poland

Andrzej Szczudlik1 Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, Poland

Agnieszka Slowik1 Department of Neurology, Jagiellonian University, School of Medicine, Botaniczna, Poland

show all

Pages 1029-1033 | Published online: 29 Jul 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

CacabelosRInfluence of pharmacogenetics factors on Alzheimer’s disease therapeuticsNeurodegener Dis200853–417617818322383
PubMed Web of Science ®Google Scholar
CacabelosRLlovoRFraileCFernandez-NovoaLPharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogeneticsCurr Alzheimer Res20074447950017908053
PubMed Web of Science ®Google Scholar
Human Cytochrome P450 (CYP) Allele Nomenclature Committee Available from: http://www.cypalleles.ki.se/Accessed September 4, 2012
Google Scholar
ZangerUMFischerJRaimundoSComprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6Pharmacogenetics200111757358511668217
PubMedGoogle Scholar
GaedigkARyderDLBradfordLDLeederJSCYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the −1584G promoter polymorphismClin Chem2003496 Pt 11008101112766015
PubMed Web of Science ®Google Scholar
SeripaDBizzarroAPilottoARole of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s diseasePharmacogenet Genomics201121422523020859244
PubMed Web of Science ®Google Scholar
PilottoAFranceschiMD’OnofrioGEffect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer diseaseNeurology2009731076176719738170
PubMed Web of Science ®Google Scholar
AlbaniDMartinelli BoneschiFBiellaGReplication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patientsJ Alzheimers Dis201230474574922465999
PubMed Web of Science ®Google Scholar
McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer’s diseaseNeurology19843479399446610841
PubMed Web of Science ®Google Scholar
Klimkowicz-MrowiecASlowikAKrzywoszanskiLHerzog- KrzywoszanskaRSzczudlikASeverity of explicit memory impairment due to Alzheimer’s disease improves effectiveness of implicit learningJ Neurol2008255450250918350358
PubMed Web of Science ®Google Scholar
National Institute for Health and Clinical Excellence Available from: http://www.nice.org.uk/nicemedia/live/13419/5361Accessed July 2, 2013
Google Scholar
WilkinsonDSchindlerRSchwamEEffectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer’s diseaseDement Geriatr Cogn Disord200928324425119786776
PubMed Web of Science ®Google Scholar
YangYHWuSLChouMCLaiCLChenSHLiuCKPlasma concentration of donepezil to the therapeutic response of Alzheimer’s disease in TaiwaneseJ Alzheimers Dis201123339139721098979
PubMed Web of Science ®Google Scholar
RigaudASTraykovLLatourFPresence or absence of at least one ε4 allele and gender are not predictive for the response to treatment with donepezil in Alzheimer’s diseasePharmacogenetics200212541542012142731
PubMedGoogle Scholar
PoirierJDelisleMCQuirionRApolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer diseaseProc Natl Acad Sci USA1995922612260122648618881
PubMed Web of Science ®Google Scholar
AlmkvistOJelicVAmberlaKResponder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patientsDement Geriat Cogn Disord20011212232
Web of Science ®Google Scholar
AerssensJRaeymaekersPLilienfeldSAPOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s diseaseDement Geriatr Cogn Disord2001122697711173877
PubMed Web of Science ®Google Scholar
BabicTMahovic LakusicDSerticJApoE genotyping and response to galantamine in Alzheimer’s disease – a real life retrospective studyColl Antropol200428119920415636076
PubMedGoogle Scholar
BorroniBColciaghiFPastorinoLApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral modelEur Neuropsychopharmacol200212519520012007670
PubMed Web of Science ®Google Scholar
ChoiSHKimSYNaHREffect of ApoE genotype on response to donepezil in patients with Alzheimer’s diseaseDement Geriatr Cogn Disord200825544545018401173
PubMed Web of Science ®Google Scholar
Darreh-ShoriTMeurlingLPetterssonTChanges in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic treatment with donepezilJ Neural Transm2006113111791180116868793
PubMed Web of Science ®Google Scholar
SramekJJCutlerNRRBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?Alzheimer Dis Assoc Disord200014421622711186600
PubMed Web of Science ®Google Scholar
VarsaldiFMiglioGScordoMGImpact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patientsEur J Clin Pharmacol200962972172616845507
PubMed Web of Science ®Google Scholar
ChianellaCGragnanielloDMaisano DelserPBCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitorsEur J Clin Pharmacol201167111147115721630031
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer’s disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer’s disease

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date